The Efficacy and Safety of a Compound Glutamine Capsule in the Prevention of Chemotherapy-induced Mucositis
NCT04988971 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2021-10-15
Summary
Chemotherapy regimens not only improve the survival of patients with gastric cancer and colorectal cancer, but also cause obvious adverse reactions of digestive tract, such as chemotherapy-induced oral mucositis, abdominal pain, diarrhea, constipation and so on. These adverse reactions seriously affect the patients' quality of life and the efficacy of chemotherapy. Glutamine is a conditionally essential amino acid in the human body. Previous studies have shown that oral glutamine can help to keep the integrity of mucosal epithelium during chemotherapy and reduce the gastrointestinal side effects caused by chemotherapy. The addition of glutamine to parenteral nutrition can better maintain nitrogen balance and reduce the incidence of infection-related complications. A compound glutamine capsule, composed of L-glutamine and the traditional Chinese herbal formula Si-Jun-Zi-Tang which composed of ginseng, Atractylodes macrocephala, Poria cocos and licorice, has been widely used in China for 23 years to treat many types of gastrointestinal diseases, including gastrointestinal reactions induced by radiotherapy and chemotherapy, ulcerative colitis, irritable bowel syndrome. However, so far, only a small sample of clinical trials have explored the role of glutamine in chemical mucositis, and there is a lack of prospective randomized controlled clinical trials to further verify its value in the prevention and treatment of chemical mucositis. The purpose of this study is to observe the efficacy and safety between a compound glutamine capsule and placebo in the prevention of chemotherapy-induced mucositis in patients with gastric cancer and colorectal cancer in a prospective, randomized, double-blind clinical trial.
Conditions
- Mucositis
- Chemotherapeutic Toxicity
Interventions
- DRUG
-
a compound glutamine capsule
A compound glutamine capsule was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
- DRUG
-
a compound glutamine capsule simulated placebo
a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Sponsors & Collaborators
-
Meng Qiu
lead OTHER
Principal Investigators
-
meng qiu, Doctor · West China Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-06-30
- Primary Completion
- 2022-07-01
- Completion
- 2022-12-31
Countries
- China
Study Locations
More Related Trials
-
Effects of Oral L-Glutamine in Head and Neck Cancer Patients During Radiotherapy
NCT03015077 ·Status: COMPLETED ·Phase: NA
-
S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat
NCT00006994 ·Status: TERMINATED ·Phase: PHASE3
-
Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis
NCT06031012 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy
NCT06472739 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.
NCT06354712 ·Status: RECRUITING ·Phase: PHASE2
-
Oral Glutamine and Thoracic/Upper Aerodigestive Tumors Radiation Toxicity
NCT05054517 ·Status: COMPLETED
-
Effect of N-Acetyl Cysteine (NAC) on the Oral Microbiome
NCT03982537 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
NCT05892354 ·Status: RECRUITING ·Phase: NA
-
Effect of Arginine and Glutamine on Radiation-induced Oral Mucositis: a Trible Blinded Randomized Controlled Clinical Trial
NCT06764420 ·Status: COMPLETED ·Phase: NA
-
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
NCT00503776 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of N-acetyl Cysteine and Zinc in Management of Head and Neck Cancer Radiotherapy Induced Oral Mucositis
NCT06482034 ·Status: COMPLETED ·Phase: PHASE2
-
Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy
NCT03647527 ·Status: UNKNOWN
-
Randomised Study of Mucositis Prevention After Radiochemotherapy Treatment for Head and Neck Cancer
NCT01149642 ·Status: COMPLETED ·Phase: NA
-
Effect of Oral Enteral Nutrition in Nasopharyngeal Carcinoma Survivors With Swallowing Disorders
NCT06301672 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma
NCT02945878 ·Status: UNKNOWN
-
Omega-3 Hydrogel and Prevention of Oral Mucositis
NCT05214495 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
NCT00728585 ·Status: WITHDRAWN ·Phase: PHASE2
-
Oral Enteral Nutrition in Delayed Onset Radiotherapy-related Swallowing Disorder in Nasopharyngeal Carcinoma
NCT06301763 ·Status: COMPLETED ·Phase: NA
-
Effect of Arginine- and Glutamine-based Oral Formulations on Salivary Biomarkers and Clinical Severity of Radiation-induced Oral Mucositis in Head and Neck Cancer: A Randomized Controlled Trial
NCT07020754 ·Status: COMPLETED ·Phase: PHASE2
-
N Acetylcystene in Treatment of Radiotherapy Induced Oral Mucositis in Oral Cancer Patients
NCT07082621 ·Status: COMPLETED ·Phase: NA
-
EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer
NCT00574860 ·Status: TERMINATED ·Phase: PHASE3
-
A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
NCT06287788 ·Status: RECRUITING
-
Evaluating Chinese Medicine Oral Rinse for Irradiated Oral Mucositis in Head & Neck Cancer Patients
NCT05664906 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer
NCT00360971 ·Status: TERMINATED ·Phase: PHASE3
-
Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment
NCT03228147 ·Status: COMPLETED ·Phase: NA